Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide

SUPPLEMENTARY FIGURES AND TABLES Supplementary
: Induction of extrinsic and intrinsic apoptotic pathways following treatment with TRAIL monotherapy and TRAIL and TMZ combined therapy. A. Cleavage of caspase-8 and caspase-3 was assessed in A172 and MZ304 cells following treatment with TRAIL (100 ng/ml) in the presence or absence of zVAD-fmk (150 μM) for 24 and 96 h, respectively. Cleavage of caspase-8 and caspase-3 was observed in the TRAIL-sensitive cell line, A172, but not in the TRAIL-resistant cell line, MZ304. In both cases, this cleavage was prevented by zVAD-fmk (n=3). B. Percentage of AnnexinV + A172 and MZ304 cells following treatment with TRAIL (100 ng/ml) in the presence or absence of zVAD-fmk (150 μM) for 96 h. The percentage of AnnexinV + cells was significantly increased in the TRAIL-responsive cell line, A172, but not in the TRAIL-resistant cell line, MZ304. This increase in AnnexinV + A172 cells following TRAIL treatment was prevented by zVAD-fmk. Data are presented as mean ± SEM from n = 3 independent experiments. One-way ANOVA with post hoc Bonferroni test was performed for statistical analysis. C. Cleavage of PARP was assessed in U251 and MZ294 cells following the combined treatment of TRAIL (100 ng/ml) and TMZ (150 μM) in the presence or absence of zVAD-fmk (150 μM) for 48 h. Cleavage of PARP was observed in the TRAIL/TMZ-sensitive cell line, U251, but not in the TRAIL/TMZ-resistant cell line, MZ294. This cleavage was prevented by zVAD-fmk (n=3). D. Percentage of apoptotic cells following the combined treatment with TRAIL (100 ng/ml) and TMZ (150 μM) for 48 h. Apoptotic cell death, as assessed by nuclear fragmentation was significantly higher in the TRAIL/TMZ-sensitive cell line, U251, compared to untreated controls. No apoptotic cell death was detected in the TRAIL/TMZ-resistant cell line, MZ294. Data are presented as mean ± SEM from n = 3 independent experiments. Student's t test. E. Caspase-3 substrate cleavage was assessed in U251 and MZ294 cells following TRAIL (100 ng/ml) and TMZ (150 μM) treatment for 48 h. Caspase-3 substrate cleavage was significantly increased in the TRAIL/TMZ-sensitive cell line, U251, compared to untreated controls. No such increase was observed in the TRAIL/TMZ-resistant cell line, MZ294. Data are presented as mean ± SEM from n = 3 independent experiments. Student's t test. **p<0.01, ***p<0.001. 
